Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel.

Journal Article (Multicenter Study;Journal Article)

Untargeted metabolomics is used to refine the development of biomarkers for the diagnosis of cardiovascular disease. Myocardial infarction (MI) has major individual and societal consequences for patients, who remain at high risk of secondary events, despite advances in pharmacological therapy. To monitor their differential response to treatment, we performed untargeted plasma metabolomics on 175 patients from the platelet inhibition and patient outcomes (PLATO) trial treated with ticagrelor and clopidogrel, two common P2 Y12 inhibitors. We identified a signature that discriminates patients, which involves polyunsaturated fatty acids (PUFAs) and particularly the omega-3 fatty acids docosahexaenoate and eicosapentaenoate. The known cardiovascular benefits of PUFAs could contribute to the efficacy of ticagrelor. Our work, beyond pointing out the high relevance of untargeted metabolomics in evaluating response to treatment, establishes PUFA metabolism as a pathway of clinical interest in the recovery path from MI.

Full Text

Duke Authors

Cited Authors

  • Samman, KN; Mehanna, P; Takla, E; Grenier, J-C; Chan, MY; Lopes, RD; Neely, ML; Wang, TY; Newby, LK; Becker, RC; Lordkipanidzé, M; Ruiz, M; Hussin, JG; Jolicœur, EM

Published Date

  • June 4, 2021

Published In

Volume / Issue

  • 2 / 6

Start / End Page

  • 100299 -

PubMed ID

  • 34195679

Pubmed Central ID

  • PMC8233657

Electronic International Standard Serial Number (EISSN)

  • 2666-3791

International Standard Serial Number (ISSN)

  • 2666-3791

Digital Object Identifier (DOI)

  • 10.1016/j.xcrm.2021.100299


  • eng